NeoGenomics Inc. (NEO) shares surged 10.24% in pre-market trading on Tuesday following the release of its impressive third-quarter 2025 financial results. The cancer diagnostics company reported better-than-expected revenue and earnings, demonstrating robust growth in its clinical services segment.

For the third quarter, NeoGenomics posted consolidated revenue of $187.8 million, representing a 11.9% increase compared to the same period last year. This figure surpassed Wall Street analysts' expectations of $183.8 million. The company's clinical revenue grew by an impressive 18%, driven by a 15% rise in clinical test volumes. Notably, next-generation sequencing (NGS) revenue saw a significant 24% year-over-year growth, now accounting for nearly one-third of clinical revenue.

On the earnings front, NeoGenomics reported adjusted earnings per share of $0.03, beating the consensus estimate of $0.02. While this represents a decrease from $0.05 per share in the prior year, it still exceeded market expectations. The company's adjusted EBITDA for the quarter was $12.2 million, showcasing its operational efficiency despite ongoing investments in growth initiatives. In light of these results, NeoGenomics reaffirmed its full-year 2025 guidance for revenue, net loss, and adjusted EBITDA, instilling confidence in investors about its future performance.